Correlation Between Kiniksa Pharmaceuticals and Nuvalent
Can any of the company-specific risk be diversified away by investing in both Kiniksa Pharmaceuticals and Nuvalent at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Kiniksa Pharmaceuticals and Nuvalent into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Kiniksa Pharmaceuticals and Nuvalent, you can compare the effects of market volatilities on Kiniksa Pharmaceuticals and Nuvalent and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Kiniksa Pharmaceuticals with a short position of Nuvalent. Check out your portfolio center. Please also check ongoing floating volatility patterns of Kiniksa Pharmaceuticals and Nuvalent.
Diversification Opportunities for Kiniksa Pharmaceuticals and Nuvalent
0.16 | Correlation Coefficient |
Average diversification
The 3 months correlation between Kiniksa and Nuvalent is 0.16. Overlapping area represents the amount of risk that can be diversified away by holding Kiniksa Pharmaceuticals and Nuvalent in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Nuvalent and Kiniksa Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Kiniksa Pharmaceuticals are associated (or correlated) with Nuvalent. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Nuvalent has no effect on the direction of Kiniksa Pharmaceuticals i.e., Kiniksa Pharmaceuticals and Nuvalent go up and down completely randomly.
Pair Corralation between Kiniksa Pharmaceuticals and Nuvalent
Given the investment horizon of 90 days Kiniksa Pharmaceuticals is expected to under-perform the Nuvalent. In addition to that, Kiniksa Pharmaceuticals is 2.1 times more volatile than Nuvalent. It trades about -0.26 of its total potential returns per unit of risk. Nuvalent is currently generating about 0.08 per unit of volatility. If you would invest 9,269 in Nuvalent on August 28, 2024 and sell it today you would earn a total of 293.00 from holding Nuvalent or generate 3.16% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 95.45% |
| Values | Daily Returns |
Kiniksa Pharmaceuticals vs. Nuvalent
Performance |
| Timeline |
| Kiniksa Pharmaceuticals |
| Nuvalent |
Kiniksa Pharmaceuticals and Nuvalent Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Kiniksa Pharmaceuticals and Nuvalent
The main advantage of trading using opposite Kiniksa Pharmaceuticals and Nuvalent positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Kiniksa Pharmaceuticals position performs unexpectedly, Nuvalent can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nuvalent will offset losses from the drop in Nuvalent's long position.| Kiniksa Pharmaceuticals vs. Nuvalent | Kiniksa Pharmaceuticals vs. Ventyx Biosciences | Kiniksa Pharmaceuticals vs. Arcellx | Kiniksa Pharmaceuticals vs. Cullinan Oncology LLC |
| Nuvalent vs. Eliem Therapeutics | Nuvalent vs. HCW Biologics | Nuvalent vs. Scpharmaceuticals | Nuvalent vs. Milestone Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Complementary Tools
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |